Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 2.04% and Operating profit at -3.63% over the last 5 years
3
Flat results in May 25
4
With ROE of 8.17%, it has a very attractive valuation with a 1.25 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 328,771 Million (Mid Cap)
15.00
NA
0.09%
-0.43
7.50%
1.22
Revenue and Profits:
Net Sales:
34,665 Million
(Quarterly Results - May 2025)
Net Profit:
2,637 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.69%
0%
-4.69%
6 Months
-0.69%
0%
-0.69%
1 Year
-1.68%
0%
-1.68%
2 Years
-9.77%
0%
-9.77%
3 Years
7.38%
0%
7.38%
4 Years
6.28%
0%
6.28%
5 Years
-32.82%
0%
-32.82%
Hisamitsu Pharmaceutical Co., Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.04%
EBIT Growth (5y)
-3.63%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.53
Tax Ratio
21.89%
Dividend Payout Ratio
30.45%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
10.13%
ROE (avg)
5.31%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.25
EV to EBIT
11.58
EV to EBITDA
8.67
EV to Capital Employed
1.45
EV to Sales
1.40
PEG Ratio
0.31
Dividend Yield
0.11%
ROCE (Latest)
12.52%
ROE (Latest)
8.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Aug 2018
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'25 - YoY
May'25
May'24
Change(%)
Net Sales
34,665.00
35,810.00
-3.20%
Operating Profit (PBDIT) excl Other Income
5,056.00
5,563.00
-9.11%
Interest
2.00
4.00
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,637.00
4,971.00
-46.95%
Operating Profit Margin (Excl OI)
97.10%
115.90%
-1.88%
USD in Million.
Net Sales
YoY Growth in quarter ended May 2025 is -3.20% vs 11.57% in May 2024
Consolidated Net Profit
YoY Growth in quarter ended May 2025 is -46.95% vs 18.95% in May 2024
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
156,006.00
141,706.00
10.09%
Operating Profit (PBDIT) excl Other Income
25,231.00
18,340.00
37.57%
Interest
23.00
18.00
27.78%
Exceptional Items
-343.00
-894.00
61.63%
Consolidate Net Profit
22,301.00
14,431.00
54.54%
Operating Profit Margin (Excl OI)
121.10%
92.90%
2.82%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is 10.09% vs 10.42% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is 54.54% vs 19.01% in Feb 2024
About Hisamitsu Pharmaceutical Co., Inc. 
Hisamitsu Pharmaceutical Co., Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






